New immunotherapy combo shows promise for bladder cancer patients who Can't take chemo

NCT ID NCT02845323

First seen Apr 07, 2026 · Last updated May 14, 2026 · Updated 10 times

Summary

This study tests whether adding urelumab to nivolumab (both immunotherapy drugs) before bladder removal surgery improves the immune response against muscle-invasive bladder cancer. It includes 15 patients who either cannot receive standard chemotherapy due to health reasons or choose not to. The main goal is to measure immune cell activity in the removed bladder tissue.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Columbia University Medical Center

    New York, New York, 10032, United States

  • Johns Hopkins Hospital

    Baltimore, Maryland, 21205, United States

  • UCLA Institute of Urologic Oncology

    Los Angeles, California, 90095, United States

  • University of Chicago

    Chicago, Illinois, 60637, United States

  • University of Colorado Cancer Center

    Aurora, Colorado, 80045, United States

Conditions

Explore the condition pages connected to this study.